TSK Laboratory, Japan appears in FDA premarket records as the applicant for K262516, a Traditional 510(k) for a device named TSK OptiXion. The filing carries product code QYM, regulation number 880.5570 and device class 2, with the openFDA device name listed as Ophthalmic Needle. FDA recorded receipt on 21 July 2026 and a substantially equivalent decision on 6 October 2026. The company's own launch notice, dated 23 October 2026, describes TSK OptiXion™ Needle and TSK OptiXion™ Viscoelastic Cannula as new ophthalmic products, which places the cleared filing alongside a documented product family rather than an isolated submission. [1][2][4]
The K262516 filing and its scope
The FDA record identifies TSK Laboratory, Japan as applicant, with a Tochigi-Ken address and country code JP. The submission is a Traditional 510(k), not reviewed by a third party, with a Summary available and the advisory committee listed as General Hospital (HO). The decision code SESE corresponds to a substantially equivalent decision description. The supplied collection holds one linked record, this 510(k), and the decision count for the full collection is one SESE; the record sample likewise contains one entry, so no broader portfolio total should be inferred from either figure. [1][2]
The FDA 510(k) database page for K262516 repeats the General Hospital review panel, the Traditional submission type, the absence of third-party review, and the absence of a combination product designation or an authorized predetermined change control plan. It also links the Summary document. These fields describe the administrative shape of one clearance; they do not establish clinical performance, manufacturing capacity or commercial uptake. [2]
Documented ophthalmic products
TSK Laboratory's launch notice announces the TSK OptiXion™ Needle and TSK OptiXion™ Viscoelastic Cannula. The needle lineup is listed at 34G×9mm, 33G×9mm, 32G×9mm, 32G×13mm and 30G×13mm, each with a product code and a quantity of 50 pcs/box. The viscoelastic cannula lineup is listed at 27G×22mm and 25G×22mm, also at 50 pcs/box. The notice states that launch-date details by country are available from a sales representative, so availability outside that statement is unknown. [4]
The company's injection devices page lists TSK OptiXion™ Needle and TSK OptiXion™ Viscoelastic Cannula as new items within a product group that also includes TSK Select™ Needle, STERiJECT™ and STERiGLIDE®. A news listing dated 23 October 2026 carries the launch notice for the two OptiXion products and a separate notice on new specifications for TSK SELECT™ NEEDLE. These pages are published by TSK Laboratory, Japan and describe its own catalog. [6][7]
Company identity and published details
The company's Japanese-language company page gives the corporate name 株式会社タスク, English name TSK Laboratory, Japan, a founding date of 17 October 1974, stated capital of 30 million yen, 292 employees as of 1 October 2026, and business lines covering manufacture, sale and export of medical devices. It lists biopsy needles, injection needles, syringes, special needles, other products and OEM products among main products, and states sales through 150 domestic and overseas distributors in 30 countries. It also names a China entity, TSK Laboratory, China Co.,Ltd, in Shanghai. [5]
The company's English site presents product categories for biopsy needles, injection devices, syringes and others, and links to ISO13485 and ISO14001 certification notices. The FDA filing address at 1510-1, Soja-Machi, Tochigi-Shi matches the address published on the company site; the filing itself is a regulatory record, not a statement of corporate headquarters. No parent, brand owner or affiliate relationship beyond the named China entity is verified in these sources. [1][3][5]
What the record does and does not show
The documented regulatory event is a single 510(k) clearance for a device named TSK OptiXion under product code QYM, decided 6 October 2026, followed by a company launch notice dated 23 October 2026 for two OptiXion products. The public documents do not include recall records, post-market data, clinical outcome results or independent testing, and none should be assumed from the clearance. [1][4]

